Quantification of osteopontin in human plasma with an ELISA: Basal levels in pre- and postmenopausal women

Clinical Biochemistry

Volumn 29, Issue 3, 1996, Pages 231-239

  Bautista, Diosdado S ^a   Saad, Zahida ^a   Chambers, Ann F ^a   Tonkin, Katia S ^a   O'Malley, Frances P ^a   Singhal, Hemant ^a   Tokmakejian, Sonya ^a   Bramwell, Vivien ^a   Harris, John F ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

ELISA; menstrual cycle; sialoglycoproteins

Indexed keywords

LUTEINIZING HORMONE; OSTEOPONTIN; PROGESTERONE;

ADULT; ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN EXPERIMENT; MENSTRUAL CYCLE; NORMAL HUMAN; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION;

EID: 0029998936     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/0009-9120(96)84728-A     Document Type: Article

References (41)

1. Denhardt DT, Guo X: Osteopontin: a protein with diverse functions. FASEB J 1993; 7: 1475-82.
2. Butler WT: The nature and significance of osteopontin. Connect Tissue Res 1989; 23: 123-36.
3. Patarca R, Saavedra RA, Cantor H: Molecular and cellular basis of genetic resistance to bacterial infection: the role of the early T-lymphocyte activation-1/ osteopontin gene. Crit Rev Immunol 1993; 13: 225-46.
4. Giachelli CM, Schwartz SM, Liaw L: Molecular and cellular biology of osteopontin. Potential role in cardiovascular disease. Trends Cardiovasc Med 1995; 5: 88-95.
5. Chackalaparampil I, Banerjee D, Poiriere Y, Mukherjee BB: Altered processing of a major secreted phosphoprotein correlates with tumorigenecity in Rous sarcoma virus-transformed mammalian cells. J Virol 1985; 53: 841-50.
6. Laverdure GR, Banerjee D, Poiriere Y, Mukherjee BB: Epidermal and transforming growth factors modulate secretion of a 69 kDa phosphoprotein in normal rat kidney fibroblasts. FEBS Lett 1983; 222: 261-5.
7. Senger DR, Asch BB, Smith BD, Perruzzi CA, Dvorak HF: A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 1983; 302: 714-5.
8. Senger DR, Perruzzi CA, Gracey CR, Papadopoulos A, Tenen DG: Secreted phosphoproteins associated with neoplastic transformation: close homology with plasma proteins cleaved during blood coagulation. Cancer Res 1988; 48: 5770-4.
9. Senger DR, Perruzzi CA, Papadopoulos A: Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989; 9: 1291-9.
10. Senger DR, Wirth DR, Hynes RO: Transformed mammalian cells secrete specific proteins and phosphoproteins. Cell 1979; 16: 885-93.
11. Craig AM, Nemir M, Mukherjee BB, Chambers AF, Denhardt DT: Identification of the major phosphoprotein secreted by many rodent cell lines as 2ar/ osteopontin: enhanced expression in H-ras-transformed 3T3 cells. Biochem Biophys Res Commun 1988; 157: 166-73.
12. Chambers AF, Behrend EI, Wilson SM, Denhardt DT: Induction of expression of osteopontin (OPN; secreted phosphoprotein) in metastatic, ras-transformed NIH 3T3 cells. Anticancer Res 1992; 12: 43-7.
13. Craig AM, Bowden GT, Chambers AF, et al.: Secreted phosphoprotein mRNA is induced during multi-stage carcinogenesis in mouse skin and correlates with the metastatic potential of murine fibroblasts. Int J Cancer 1990; 46: 133-7.
14. Behrend EI, Craig AM, Wilson SM, Denhardt DT, Chambers AF: Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 1994; 54: 832-7.
15. Brown LF, Papadopoulos Sergiou A, Berse B, et al.: Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-23.
16. Hirota S, Ito A, Nagoshi J, et al.: Expression of bone matrix protein messenger ribonucleic acids in human breast cancers. Possible involvement of osteopontin in development of calcifying foci. Lab Invest 1995; 72: 64-9.
17. O'Malley F, Saad Z, Harris JF et al. Osteopontin and p53 expression in lymph node negative breast cancer. Proc Am Assoc Cancer Res 1995; 36: 621 (Abstract)
18. Maeda H, Kukita T, Akamine A, Kukita A, Iijima T: Localization of osteopontin in resorption lacunae formed by osteoclast-like cells: a study by a novel monoclonal antibody which recognizes rat osteopontin. Histochemistry 1994; 102: 247-54.
19. Bellahcene A, Castronovo V: Increased expression of osteonectin and osteopontin, two bone matrix proteins, in human breast cancer. Am J Pathol 1995; 146: 95-100.
20. Saitoh Y, Kuratsu J, Takeshima H, Yamamoto S, Ushio Y: Expression of osteopontin in human glioma. Its correlation with the malignancy. Lab Invest 1995; 72: 55-63.
21. Patarca R, Freeman GJ, Singh RP, et al.: Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection. J Exp Med 1989; 170: 145-61.
22. Pollack SB, Linnemeyer PA, Gill S: Induction of osteopontin mRNA expression during activation of murine NK cells. J Leukoc Biol 1994; 55: 398-400.
23. O'Brien ER, Garvin MR, Stewart DK, et al.: Osteopontin is synthesized by macrophage, smooth muscle, and endothelial cells in primary and restenotic human coronary atherosclerotic plaques. Arterioscler Thromb 1994; 14: 1648-56.
24. Fitzpatrick LA, Severson A, Edwards WD, Ingram RT: Diffuse calcification in human coronary arteries. Association of osteopontin with atherosclerosis. J Clin Invest 1994; 94: 1597-604.
25. Ikeda T, Shirasawa T, Esaki Y, Yoshiki S, Hirokawa K: Osteopontin mRNA is expressed by smooth muscle-derived foam cells in human atherosclerotic lesions of the aorta. J Clin Invest 1993; 92: 2814-20.
26. Hirota S, Imakita M, Kohri K, et al.: Expression of osteopontin messenger RNA by macrophages in atherosclerotic plaques. A possible association with calcification. Am J Pathol 1993; 143: 1003-8.
27. Giachelli CM, Bae N, Almeida M, Denhardt DT, Alpers CE, Schwartz SM: Osteopontin is elevated during neointima formation in rat arteries and is a novel component of human atherosclerotic plaques. J Clin Invest 1993; 92: 1686-96.
28. Couser WG, Johnson RJ: Mechanisms of progressive renal disease in glomerulonephritis. Am J Kidney Dis 1994; 23: 193-8.
29. Kohri K, Nomura S, Kitamura Y, et al.: Structure and expression of the mRNA encoding urinary stone protein (osteopontin). J Biol Chem 1993; 268: 15180-4.
30. Shiraga H, Min W, VanDusen WJ, et al.: Inhibition of calcium oxalate crystal growth in vitro by uropontin: another member of the aspartic acid-rich protein superfamily. Proc Natl Acad Sci USA 1992; 89: 426-30.
31. Worcester EM, Blumenthal SS, Beshensky AM, Lewand DL: The calcium oxalate crystal growth inhibitor protein produced by mouse kidney cortical cells in culture is osteopontin. J Bone Miner Res 1992; 7: 1029-36.
32. Bautista DS, Denstedt J, Chambers AF, Harris JF: Low molecular weight variants of osteopontin generated by serine proteinases in urine of patients with kidney stones. J Cell Biochem, in press.
33. Bautista DS, Xuan JW, Hota C, Chambers AF, Harris JF: Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994; 269: 23280-5.
34. Xuan JW, Hota C, Chambers AF: Recombinant GST-human osteopontin fusion protein is functional in RGD-dependent cell adhesion. J Cell Biochem 1994; 54: 247-55.
35. Young MF, Kerr JM, Termine JD, et al.: cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN). Genomics 1990; 7: 491-502.35.
36. Prince CW, Butler WT: 1,25-Dihydroxyvitamin D3 regulates the biosynthesis of osteopontin, a bone-derived cell attachment protein, in clonal osteoblast-like osteosarcoma cells. Coll Relat Res 1987; 7: 305-13.
37. Noda M, Rodan GA: Type beta transforming growth factor regulates expression of genes encoding bone matrix proteins. Connect Tissue Res 1989; 21: 71-5.
38. Majeska RJ, Ryaby JT, Einhorn TA: Direct modulation of osteoblastic activity with estrogen. J Bone Joint Surg Am 1994; 76: 713-21.
39. Nagata T, Todescan R, Goldberg HA, Zhang Q, Sodek J: Sulphation of secreted phosphoprotein I (SPPI, osteopontin) is associated with mineralized tissue formation. Biochem Biophys Res Commun 1989; 165: 234-40.
40. Hunter GK, Kyle CL, Goldberg HA: Modulation of crystal formation by bone phosphoproteins: structural specificity of the osteopontin-mediated inhibition of hydroxyapatite formation. Biochem J 1994; 300: 723-8.
41. Ek-Rylander B, Flores M, Wendel M, Heinegard D, Andersson G: Dephosphorylation of osteopontin and bone sialoprotien by osteoclastic tartrate-resistant acid phosphatase. Modulation of osteoclast adhesion in vitro. J Biol Chem 1994; 269: 14853-6.